Hikma Set For Ryaltris Take Off As Glenmark Wins USFDA Nod

Companies Partnered Up In March 2020; Ryaltris Already Rolled-Out In Europe

Glenmark is celebrating a “major milestone,” after its Ryaltris nasal spray to treat seasonal allergic rhinitis was approved by the FDA. Hikma will handle commercialization in the US, as part of its continued specialty push in the market.

Nasal_Spray
Hikma has described Ryaltris as "very interesting" • Source: Shutterstock

More from Products

More from Generics Bulletin